Health state utility values in locally advanced and metastatic breast cancer by treatment line: a systematic review-Reference-Cited by-同舟云学术

Health state utility values in locally advanced and metastatic breast cancer by treatment line: a systematic review

Published:2016-08-30 Issue:5 Volume:16 Page:549-559
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Paracha Noman¹,Thuresson Per-Olof¹,Moreno Santiago G.²,MacGilchrist Katherine S.³

Affiliation:

1. F Hoffmann-La Roche AG, MORSE Health Technology Assessment Group, Basel, Switzerland

2. Novartis Pharma AG, Market Access Oncology Region Europe, Basel, Switzerland

3. Epidemica Ltd., Systematic Review Department, Bicester, UK

Funder

F Hoffmann-La Roche AG, Basel, Switzerland

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2016.1222907

Reference71 articles.

1. Ferlay J, Soerjomataram I, Globocan ME 2012 v1.1, Cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer [Internet]. 2014 [cited 2016 Feb]. Available from: http://globocan.iarc.fr.

2. Deriving a Patient-Based Utility Index from a Cancer-Specific Quality of Life Questionnaire

3. Stage at diagnosis and early mortality from cancer in England

4. Symptom Management in Metastatic Breast Cancer

5. Breast cancer as a systemic disease: a view of metastasis

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review of health state utility values for older people with acute myeloid leukaemia;Quality of Life Research;2024-08-22

2. Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain;PharmacoEconomics - Open;2024-08-19

3. Quality Appraisal in Systematic Literature Reviews of Studies Eliciting Health State Utility Values: Conceptual Considerations;PharmacoEconomics;2024-03-29

4. Health utility values of breast cancer treatments and the impact of varying quality of life assumptions on cost‐effectiveness;International Journal of Cancer;2024-03-13

5. Cost-effectiveness of Metronomic chemotherapy vs Weekly Intravenous Paclitaxel in patients with ER+/HER2-Metastatic Breast Cancer;2024-01-23